Order vaccine<\/i><\/a>\nWastage<\/h3>\n
Wastage should be reported weekly.<\/p>\n
Because the vaccine is licensed for one dose per vial, wastage will be considered as any wastage of a full vial of vaccine for any reason. If you administer at least one dose, using either ID or SubQ administration, you do not need to report wastage on that vial.<\/p>\n
\n- Guide: Mpox Vaccine Wastage Guide<\/a><\/li>\n
- Video: How to add vaccine wastage to PhilaVax<\/a><\/li>\n<\/ul>\n
Managing Vaccine Inventory<\/h3>\n
A mpox inventory has been set-up in PhilaVax to track JYNNEOS doses in sites\u2019 inventory. A\u202freconciliation must be completed weekly (every 7 calendar days)<\/span>.<\/p>\nInventory will reflect the number of vials currently on hand, not the number of doses.<\/p>\n
\n- Guide to Reconciliation<\/a><\/li>\n
- Guide: Accepting Shipments in PhilaVax<\/a><\/li>\n
- Guide: Inventory & Administration Reporting <\/a><\/li>\n<\/ul>\n
Administration Resources & Clinical Considerations<\/h2>\nDosage, Administration, and Route<\/h3>\n
JYNNEOS vaccine is licensed as a series of two doses administered 28 days (4 weeks) apart.<\/p>\n
The standard regimen involves a subcutaneous (SubQ)<\/span> route of administration with an injection volume of 0.5mL<\/span>. The standard regimen is the FDA-approved dosing regimen. Since August 9, 2022, the standard regimen has been authorized for people aged <18 years under an Emergency Use Authorization.<\/p>\nIn the context of the current national Public Health Emergency (PHE), an alternative regimen may be used for people age \u226518 years under an Emergency Use Authorization<\/a> beginning August 9, 2022. The authorized alternative regimen involves an intradermal (ID)<\/span> route of administration with an injection volume of 0.1mL<\/span>.<\/p>\nThis approach could increase the number of available JYNNEOS vaccine doses by up to<\/span> five-fold.<\/p>\nResults from a clinical study showed that the lower intradermal dose was immunologically non-inferior to the standard subcutaneous dose.<\/p>\n
\n
\n\n\n| JYNNEOS vaccine regimen<\/th>\n | Route of administration<\/th>\n | Injection volume<\/th>\n | Recommended number of doses<\/th>\n | Recommended interval between 1st and 2nd dose<\/th>\n<\/tr>\n |
\n| Alternative regimen<\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n<\/tr>\n |
\n| People age \u2265 18<\/td>\n | ID<\/td>\n | 0.1mL<\/td>\n | 2<\/td>\n | 28 days<\/td>\n<\/tr>\n |
\n| Standard regimen<\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n | <\/td>\n<\/tr>\n |
\n| People age < 18<\/td>\n | Subcut<\/td>\n | 0.5mL<\/td>\n | 2<\/td>\n | 28 days<\/td>\n<\/tr>\n |
\n| People of any age who have a history of developing keloid scars<\/td>\n | Subcut<\/td>\n | 0.5mL<\/td>\n | 2<\/td>\n | 28 days<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n Intradermal administration involves injecting the vaccine superficially between the epidermis and the hypodermis layers of the skin, typically of the inner side of the forearm.<\/p>\n Intradermal JYNNEOS administration can be considered for most adults ages 18 years and older. Exceptions include people with a history of developing keloid scars. It is not required to observe patients after vaccination.<\/p>\n \n- Coadministration of JYNNEOS Vaccine with Other Vaccines<\/a><\/li>\n
- Intradermal Preparation and Administration Summary<\/a><\/li>\n
- Clinician FAQs<\/a><\/li>\n
- Mpox Vaccine Information Statement<\/a><\/li>\n
- JYNNEOS Vaccine Dose Tracker<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"
Mpox Vaccine Eligibility Anyone in Philadelphia who is likely to be exposed to mpox can get the vaccine. People likely to be exposed to mpox are: Gay, bisexual, or other men who have sex with men or transgender, nonbinary, or gender-diverse people who in the…<\/p>\n","protected":false},"author":23,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[143],"tags":[],"class_list":["post-11453","post","type-post","status-publish","format-standard","hentry","category-mpox"],"_links":{"self":[{"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/posts\/11453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/comments?post=11453"}],"version-history":[{"count":0,"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/posts\/11453\/revisions"}],"wp:attachment":[{"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/media?parent=11453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/categories?post=11453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vaccines.phila.gov\/index.php\/wp-json\/wp\/v2\/tags?post=11453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} |